Recent Analysts’ Ratings Updates for Protagonist Therapeutics (PTGX)

Several brokerages have updated their recommendations and price targets on shares of Protagonist Therapeutics (NASDAQ: PTGX) in the last few weeks:

• 9/1/2026 – Protagonist Therapeutics had its price target raised by Barclays PLC from $153.00 to $180.00. They now have an “overweight” rating on the stock.
• 9/1/2026 – Protagonist Therapeutics had its price target raised by BMO Capital Markets from $178.00 to $190.00. They now have an “outperform” rating on the stock.
• 8/31/2026 – Protagonist Therapeutics had its price target raised by Citigroup Inc. from $175.00 to $182.00. They now have a “buy” rating on the stock.
• 8/31/2026 – Protagonist Therapeutics had its “outperform” rating reaffirmed by Citigroup Inc..
• 8/31/2026 – Protagonist Therapeutics had its “outperform” rating reaffirmed by Wolfe Research.
• 8/31/2026 – Protagonist Therapeutics had its price target raised by HC Wainwright from $167.00 to $170.00. They now have a “buy” rating on the stock.
• 8/22/2026 – Protagonist Therapeutics was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 8/17/2026 – Protagonist Therapeutics had its price target raised by BMO Capital Markets from $112.00 to $178.00. They now have an “outperform” rating on the stock.
• 8/11/2026 – Protagonist Therapeutics was upgraded by Weiss Ratings from “sell (d+)” to “hold (c+)”.
• 8/10/2026 – Protagonist Therapeutics had its price target raised by Truist Financial Corporation from $145.00 to $170.00. They now have a “buy” rating on the stock.
• 8/10/2026 – Protagonist Therapeutics had its price target raised by Wedbush from $118.00 to $173.00. They now have an “outperform” rating on the stock.
• 8/10/2026 – Protagonist Therapeutics was upgraded by UBS Group AG to “buy”.
• 8/10/2026 – Protagonist Therapeutics was upgraded by The Goldman Sachs Group, Inc. from “neutral” to “buy”. They now have a $186.00 price target on the stock, up from $110.00.
• 8/8/2026 – Protagonist Therapeutics was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 8/7/2026 – Protagonist Therapeutics was downgraded by Zacks Research from “strong-buy” to “hold”.
• 8/6/2026 – Protagonist Therapeutics had its price target raised by Barclays PLC from $151.00 to $153.00. They now have an “overweight” rating on the stock.
• 8/6/2026 – Protagonist Therapeutics had its price target raised by Citigroup Inc. from $130.00 to $175.00. They now have a “buy” rating on the stock.
• 7/25/2026 – Protagonist Therapeutics was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 7/17/2026 – Protagonist Therapeutics was given a new $165.00 price target by Johnson Rice.
• 7/17/2026 – Protagonist Therapeutics had its “outperform” rating reaffirmed by Citigroup Inc..
• 7/14/2026 – Protagonist Therapeutics had its price target raised by Barclays PLC from $119.00 to $151.00. They now have an “overweight” rating on the stock.

Insider Buying and Selling

In related news, Director William Waddill sold 9,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $117.94, for a total value of $1,061,460.00. Following the completion of the sale, the director owned 7,825 shares of the company’s stock, valued at $922,880.50. This trade represents a 53.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinsesh Patel sold 34,239 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $148.52, for a total value of $5,085,176.28. Following the transaction, the chief executive officer directly owned 523,478 shares in the company, valued at approximately $77,746,952.56. This represents a 6.14% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 118,000 shares of company stock valued at $16,921,379. 5.19% of the stock is currently owned by company insiders.

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.